-
Fixed-duration venetoclax plus obinutuzumab improves quality of life and geriatric impairments in FCR-unfit patients with CLL
HOVON CLL Working Group, 28 Sept 2023, In: Blood. 142, 13, p. 1131-1142 12 p.Research output: Contribution to journal › Article › Academic › peer-review
-
JAK–STAT signalling shapes the NF-κB response in CLL towards venetoclax sensitivity or resistance via Bcl-XL
Haselager, M. V., Thijssen, R., Bax, D., Both, D., de Boer, F., Mackay, S., Dubois, J., Mellink, C., Kater, A. P. & Eldering, E., Jun 2023, In: Molecular Oncology. 17, 6, p. 1112-1128 17 p.Research output: Contribution to journal › Article › Academic › peer-review
-
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
Seymour, J. F., Kipps, T. J., Eichhorst, B. F., D'Rozario, J., Owen, C. J., Assouline, S., Lamanna, N., Robak, T., de la Serna, J., Jaeger, U., Cartron, G., Montillo, M., Mellink, C., Chyla, B., Panchal, A., Lu, T., Wu, J. Q., Jiang, Y., Lefebure, M., Boyer, M., & 1 others , 25 Aug 2022, In: Blood. 140, 8, p. 839-850 12 p.Research output: Contribution to journal › Article › Academic › peer-review
- All publications